On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $88.16 which represents a slight increase of $1.87 or 2.17% from the prior close of $86.29. The stock opened at ...
Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...
Signaturefd LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.1% in the third ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...
GlobalData on MSN22h
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback